Company Overview and News

 
IndusInd Bank Limited - Allotment of ESOP/ESPS

12h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532187 INDUSINDBK

 
IndusInd Bank Limited - Analysts/Institutional Investor Meet/Con. Call Updates

14h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532187 INDUSINDBK

 
IndusInd Bank Limited - Trading Window

15h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532187 INDUSINDBK

 
IndusInd Bank Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532187 INDUSINDBK

 
An evening walk down Dalal Street | Pain continues on market, Sensex sheds 169 pts, Nifty gives up 11,250; midcaps fall

2018-09-19 moneycontrol
Equity benchmarks ended a volatile trading day on a negative note as consumer names as well as banks weighed. The Nifty ended below 11,250-mark, while the Sensex shed a little over 160 points. Rupee heading towards its low points also dented sentiment on the market.
524715 500325 INDUSINDBK RELIANCE 532978 BHRQY 533278 532454 BAJAJFINSV 532187 RIGD SUNPHARMA BHARTIARTL CLNDY COALINDIA RLNIY

4
Sensex recovers by 142 points in opening trade, Nifty above 11,300

2018-09-19 freepressjournal.in
Mumbai: The BSE Sensex rebounded over 100 points in opening trade Wednesday on value-buying in recently battered stocks amid strength in the rupee and positive global cues. The 30-share BSE index recovered by 142.26 points, or 0.38 per cent, to 37,432.93 in opening trade. The index had lost almost 800 points in the previous two sessions as rupee woes and trade war worries spooked investors. The NSE Nifty was up 50.
BAJAJ-AUTO 532977 BHRQY 533278 532215 500470 532187 AXISBANK 500570 BHARTIARTL TATAMOTORS CLNDY AXB INDUSINDBK IBN AXBKY 532454 AXBA ICICIBANK TTST TATASTEEL TATLY 532174 COALINDIA TTM

 
IndusInd Bank Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532187 INDUSINDBK

1
HDFC Bank hikes base rate by 20 bps to 9.15%, IndusInd Bank hikes MCLR by 5 bps

2018-09-17 moneycontrol
HDFC Bank, the country’s second largest private lender, has hiked its base rate by 0.20 percentage points to 9.15 percent. The new rate will be effective September 12.
UBNC ICICIBANK 532187 HDB INDUSINDBK 532174 IBN 500180 HDFCBANK SBAZ

5
Sensex tanks 400 points on weak global cues; Nifty down 100 points

2018-09-17 freepressjournal.in
Mumbai: Weak global markets amid the US-China trade concerns plunged the key Indian equity indices on Monday afternoon, with the S&P BSE Sensex losing around 400 points so far. The wider NSE Nifty50 also lost over 100 points during the intra-day trade. Among the sectors, heavy selling pressure was witnessed in banking, consumer durables and auto stocks. Globally, market sentiments were subdued on reports that the US might announce fresh tariffs on Chinese imports.
INDUSINDBK BHRQY 532454 500470 TTST 532187 TATASTEEL TATLY HDB 500180 HDFCBANK 500570 BHARTIARTL TATAMOTORS SBAZ TTM

5
Sensex cracks 350 points on profit-booking, weak global cues

2018-09-17 freepressjournal.in
Mumbai: The benchmark BSE Sensex sank over 350 points in early trade Monday after two sessions of gains as investors cashed profits in consumer durables, banking, oil & gas and PSU stocks, amid fresh weakness in the rupee and weak global cues.
YESBANK AXB INDUSINDBK 532648 YYBKY BHRQY 532215 AXBKY 532454 AXBA 532187 HDB AXISBANK 500180 HDFCBANK 500570 BHARTIARTL TATAMOTORS TTM

 
IndusInd Bank Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532187 INDUSINDBK

 
IndusInd Bank Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532187 INDUSINDBK

 
Sensex climbs 300 pts on positive economic data, rupee recovery

2018-09-14 freepressjournal.in
Mumbai: The BSE benchmark Sensex reclaimed the 38,000-mark by surging over 300 points in opening trade Friday on heavy buying by domestic institutional investors as the industrial production grew at 6.6 per cent in July and retail inflation cooled to a 10-month low.
YESBANK ALNSE INDUSINDBK 532648 YYBKY 533278 500470 TTST 532187 TATASTEEL TATLY CLNDY COALINDIA

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...